ArticlePharmacoepidemiology and drug safety2021
Validity of claims-based algorithms for selected cancers in Japan: Results from the VALIDATE-J study.
Article in Pharmacoepidemiology and drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comparative Safety Analysis of Targeted Synthetic and Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan.International journal of rheumatic diseases · 2026Article
- Development and validation of claims-based algorithms to identify interstitial lung disease among Japanese patients with cancer in routine clinical practice using real-world data sources.Frontiers in oncology · 2026Article
- Survey of perioperative treatment in muscle-invasive bladder cancer using Japanese hospital-based claims database.BMC urology · 2025Article
- Changes in Smoking Patterns and Cervical Cancer Risk: Preventive Implications from a Nationwide Japanese Cohort.Healthcare (Basel, Switzerland) · 2025Article
- Depression risk associated with spouses' diabetes and cardiovascular events: a nationwide cohort study.American journal of epidemiology · 2025Article
- Development and validation of a claims-based algorithm to identify incidents and determine the progression phases of gastric cancer cases in Japan.Journal of gastroenterology · 2025Observational
- Article
- Risk Factors Associated With Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis in a Real-World Setting in Japan.International journal of rheumatic diseases · 2024Article
- Cancer and the risk of perioperative arterial ischaemic events.European heart journal. Quality of care & clinical outcomes · 2024Article
- Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan.BMC infectious diseases · 2023Article
- Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases.Breast cancer research and treatment · 2023Article
- Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.Vaccine · 2023Article
- Validation of algorithms to identify colorectal cancer patients from administrative claims data of a Japanese hospital.BMC health services research · 2023Article
- Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications.Frontiers in oncology · 2023Article
- Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis.Intestinal research · 2023Article
- Validation of a claims-based algorithm to identify cases of ulcerative colitis in Japan.Journal of gastroenterology and hepatology · 2022Article
- Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.Cardiovascular diabetology · 2021Observational
- Validity of claims-based algorithms for selected cancers in Japan: Results from the VALIDATE-J study.Pharmacoepidemiology and drug safety · 2021Article
- Incidence and Prevalence Analysis of Non-Small-Cell and Small-Cell Lung Cancer Using Administrative Data.International journal of environmental research and public health · 2021Article
- Validity of diagnoses, procedures, and birth records in a Japanese administrative claims database for pediatric patients.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeReal-world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE-J validated claims-based algorithms for selected cancers in Japan.
methodsVALIDATE-J was a multicenter, cross-sectional, retrospective study. Disease-identifying algorithms were used to identify cancers diagnosed between January or March 2012 and December 2016 using claims data from two hospitals in Japan. Positive predictive values (PPVs), specificity, and sensitivity were calculated for prevalent (regardless of baseline cancer-free period) and incident (12-month cancer-free period; with claims and registry periods in the same month) cases, using hospital cancer registry data as gold standard.
results22 108 cancers were identified in the hospital claims databases. PPVs (number of registry cases) for prevalent/incident cases were: any malignancy 79.0% (25 934)/73.1% (18 119); colorectal 84.4% (3519)/65.6% (2340); gastric 87.4% (3534)/76.8% (2279); lung 88.1% (2066)/79.9% (1636); breast 86.4% (4959)/59.9% (3185); pancreatic 87.1% (582)/80.4% (508); melanoma 48.7% (46)/42.9% (36); and lymphoma 83.6% (1457)/77.8% (1035). Specificity ranged from 98.3% to 100% (prevalent)/99.5% to 100% (incident); sensitivity ranged from 39.1% to 67.6% (prevalent)/12.5% to 31.4% (incident). PPVs of claims-based algorithms for several cancers in patients ≥66 years of age were slightly higher than those in a US Medicare population.
conclusionsVALIDATE-J demonstrated high specificity and modest-to-moderate sensitivity for claims-based algorithms of most malignancies using Japanese claims data. Use of claims-based algorithms will enable identification of patient populations from claims databases, while avoiding direct patient identification. Further research is needed to confirm the generalizability of our results and applicability to specific subgroups of patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.